Cannabinoids in Cranial Tumor Therapy

Glioblastoma is a highly malignant form of brain cancer that has a five year survival rate of 6%. Currently, the standard of care treatment for glioblastoma consists of maximum safe surgical resection followed by radiotherapy. Accumulating evidence indicates that cannabinoids have potent anti-tumor functions and could be used successfully in the treatment of glioblastoma. The therapeutic effects of cannabinoids are measured as reduction of tumor growth, which is achieved through the inhibition of both cell generation and blood vessel formation within the tumor itself. Tumor cell death can also occur. Most importantly, a tumor’s stem cells are what enables the disease to metastasize, and cannabinoids have been shown to limit their ability to self-renew. These findings underline the importance of exploring the molecular mechanisms of the cannabinoid system in treatment of aggressive cancerous tumors.

For more information, follow the link below:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964193/